Parasitic Helminthiasis Infectious Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Parasitic Helminthiasis Infectious Disease

MalaCards integrated aliases for Parasitic Helminthiasis Infectious Disease:

Name: Parasitic Helminthiasis Infectious Disease 12 15
Helminthiasis 12 74 52 54 43 17 71
Intestinal Helminthiasis 52 71
Helminth Infections 15
Helminth Infection 12
Worm Infections 52
Worm Infection 12
Helminthosis 12


External Ids:

Disease Ontology 12 DOID:883
ICD9CM 34 120-129.99
MeSH 43 D006373
NCIt 49 C84751
SNOMED-CT 67 27601005
ICD10 32 B82.0 B83.9
UMLS 71 C0018889 C0348287

Summaries for Parasitic Helminthiasis Infectious Disease

Disease Ontology : 12 A parasitic infectious disease that occurs when part of the body is infested with parasitic worms such as cestodes, nematodes and trematodes.

MalaCards based summary : Parasitic Helminthiasis Infectious Disease, also known as helminthiasis, is related to opisthorchiasis and necatoriasis. An important gene associated with Parasitic Helminthiasis Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Praziquantel and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and skin, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals... more...

Related Diseases for Parasitic Helminthiasis Infectious Disease

Diseases related to Parasitic Helminthiasis Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)
# Related Disease Score Top Affiliating Genes
1 opisthorchiasis 33.2 SERPINA3 IL4 EPGN
2 necatoriasis 33.2 IL5 EPGN
3 enterobiasis 33.1 STH MT-CO1 EPGN
4 angiostrongyliasis 33.1 MT-CO1 IL5 IL4 IL13
5 fascioliasis 33.1 MT-CO1 IL10 EPGN
6 echinococcosis 33.1 RNASE3 MT-CO1 IL5 IL10
7 ancylostomiasis 33.1 MT-CO1 EPGN
8 clonorchiasis 33.1 STH MT-CO1 IL10 EPGN
9 hymenolepiasis 33.1 STH MT-CO1
10 toxocariasis 33.1 RNASE3 IL5 IL4 IL10 EPGN
11 taeniasis 33.0 STH MT-CO1 IL4 IL10 CD4
12 paragonimiasis 32.9 STH RNASE3 MT-CO1 IL5 IL13 EPGN
13 strongyloidiasis 32.9 STH MT-CO1 IL5 IL13 EPGN CD4
14 ascaris lumbricoides infection 32.9 TSLP STH IL5 IL13 IL10 EPGN
15 oesophagostomiasis 32.9 MT-CO1 EPGN
16 trichuriasis 32.9 STH SERPINA3 IL9 IL13 IL10 EPGN
17 dracunculiasis 32.9 STH EPGN
18 trichinosis 32.8 TSLP IL9 IL5 IL4 IL13 IL10
19 schistosomiasis 32.7 STAT6 RNASE3 IL9 IL5 IL4 IL33
20 hypereosinophilic syndrome 31.7 RNASE3 IL9 IL5 IL4 IL13 IL10
21 cysticercosis 31.7 STH MT-CO1 IL10 CD4
22 cytokine deficiency 31.7 IL9 IL5 IL13
23 ige responsiveness, atopic 31.6 STAT6 RNASE3 IL5 IL4 IL13 IL10
24 onchocerciasis 31.5 STH SRCIN1 SERPINA3 RNASE3 IL5 IL4
25 autoimmune disease 31.4 IL9 IL5 IL4 IL13 IL10 ICOSLG
26 filarial elephantiasis 31.3 STH SRCIN1 MT-CO1 IL5 IL4 IL13
27 dysentery 31.2 STH IL10 CD4 CCR6
28 loiasis 31.2 STH SRCIN1 IL5 IL4 IL13 IL10
29 colitis 31.2 IL4 IL13 IL10 ICOSLG CCR6
30 dermatitis 31.2 TSLP IL5 IL4 IL13 IL10 CCR6
31 tetanus 31.1 IL9 IL5 IL4 IL13 IL10
32 mastocytosis 31.1 IL9 IL4 IL13
33 bacterial infectious disease 31.0 SERPINA3 IL10 ICOSLG CD4 CCR6
34 scabies 31.0 IL10 CD4 CCR6
35 cutaneous leishmaniasis 31.0 IL5 IL4 IL13 IL10
36 leishmaniasis 31.0 IL5 IL4 IL13 IL10
37 ulcerative colitis 31.0 IL4 IL13 IL10 CCR6
38 crohn's disease 31.0 IL4 IL10 ICOSLG CD4 CCR6
39 pulmonary eosinophilia 30.9 RNASE3 IL5 IL4 IL13 CCR6
40 eosinophilic pneumonia 30.9 RNASE3 IL5 IL4 IL33 IL13
41 erythema multiforme 30.9 IL5 IL4 IL13
42 allergic asthma 30.9 TSLP STAT6 RNASE3 IL9 IL5 IL4
43 meningitis 30.9 IL5 IL4 IL13 IL10
44 inflammatory bowel disease 30.9 STAT6 MIR21 IL9 IL5 IL4 IL33
45 endomyocardial fibrosis 30.9 RNASE3 IL5 IL4 IL10
46 rubella 30.9 IL5 IL4 IL10
47 syphilis 30.8 SERPINA3 CD4 CCR6
48 exanthem 30.8 IL10 ICOSLG CD4 CCR6
49 pneumonia 30.8 IL5 IL4 IL13 IL10
50 allergic rhinitis 30.8 RNASE3 IL9 IL5 IL4 IL13 IL10

Graphical network of the top 20 diseases related to Parasitic Helminthiasis Infectious Disease:

Diseases related to Parasitic Helminthiasis Infectious Disease

Symptoms & Phenotypes for Parasitic Helminthiasis Infectious Disease

MGI Mouse Phenotypes related to Parasitic Helminthiasis Infectious Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 CCR6 CD4 CHRM2 EPGN IL10 IL13
2 hematopoietic system MP:0005397 10.06 CCR6 CD4 EPGN IL10 IL13 IL33
3 digestive/alimentary MP:0005381 9.97 CD4 IL10 IL13 IL33 IL4 IL5
4 immune system MP:0005387 9.93 CCR6 CD4 EPGN IL10 IL13 IL33
5 integument MP:0010771 9.65 CD4 CHRM2 EPGN IL10 IL13 IL33
6 respiratory system MP:0005388 9.23 CHRM2 IL10 IL13 IL33 IL4 IL5

Drugs & Therapeutics for Parasitic Helminthiasis Infectious Disease

Drugs for Parasitic Helminthiasis Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
Sodium citrate Approved, Investigational Phase 4 68-04-2
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
leucovorin Approved Phase 4 58-05-9 6006 143
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Iodine Approved, Investigational Phase 4 7553-56-2 807
Ferrous fumarate Approved Phase 4 141-01-5
Copper Approved, Investigational Phase 4 7440-50-8 27099
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
Pyrantel Approved, Vet_approved Phase 4 15686-83-6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Cobalamin Experimental Phase 4 13408-78-1 6857388
32 Tocotrienol Investigational Phase 4 6829-55-6
33 Benzimidazole Experimental, Investigational Phase 4 51-17-2
34 Artemether, Lumefantrine Drug Combination Phase 4
35 Vaccines Phase 4
36 Vitamins Phase 4
37 Calciferol Phase 4
38 Trace Elements Phase 4
39 Micronutrients Phase 4
40 Antioxidants Phase 4
41 Nutrients Phase 4
42 Protective Agents Phase 4
43 Citrate Phase 4
44 Piperazine citrate Phase 4
45 DMP 777 Phase 4 157341-41-8
46 Vitamin B Complex Phase 4
47 Vitamin B 12 Phase 4
48 Folate Phase 4
49 Vitamin B12 Phase 4
50 Vitamin B9 Phase 4

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
3 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
4 Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections Completed NCT00659997 Phase 4 Albendazole;Levamisole
5 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
6 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
7 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
8 Efficacy and Safety of a Single-dose Regimen and a Multi-dose Regimen of Mebendazole Against Hookworm Infections in School Children: a Randomized Controlled Trial Completed NCT03245398 Phase 4 Treatment with one of the two regimens of mebendazole
9 The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya Completed NCT02397772 Phase 4 albendazole
10 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
11 Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project Completed NCT01088958 Phase 4
12 Chengdu Women's and Children's Central Hospital Completed NCT02675140 Phase 4 ZENTEL;ZENTEL and Vitamin A Soft Capsules
13 Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon Recruiting NCT04326868 Phase 4 Benzimidazole Anthelmintic
14 Intestinal Microbiome Post-Azythromycin/Albendazole Treatment Withdrawn NCT03032042 Phase 4 Azithromycin;Albendazole;Delayed treatment
15 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam Withdrawn NCT02597556 Phase 4 Albendazole;Placebo
16 A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects Completed NCT02034162 Phase 3 Mebendazole;Placebo
17 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections Completed NCT01350271 Phase 3 Mebendazole polymorph A and C 500 mg;Mebendazole polymorph C;Placebo
18 An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive Completed NCT01173562 Phase 3 Mebendazole
19 Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial Completed NCT02073149 Phase 2, Phase 3
20 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
21 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
22 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
23 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
24 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
25 A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
26 Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming on Reducing Anemia Prevalence, and Improving Micronutrient Status, Cognitive Function, and Growth in Vietnamese School Children Completed NCT00728273 Phase 2
27 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
28 A Phase 2a, Randomized, Double Blinded, Placebo Controlled, Study Evaluating Immunity and Gluten-sensitivity by Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus. Completed NCT00671138 Phase 2
29 Efficacy and Safety of Ascending Dosages of Albendazole Against T. Trichiura and Hookworm in Preschool- and School-aged Children and Adults: a Randomized Controlled Trial Active, not recruiting NCT03527745 Phase 2 Albendazole;Albendazole;Albendazole;Albendazole;Placebo
30 Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Active, not recruiting NCT03441893 Phase 1, Phase 2 Nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg
31 Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients Not yet recruiting NCT04041453 Phase 2 Ivermectin;Albendazole
32 Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial Terminated NCT01413243 Phase 2 Trichuris suis ova
33 An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Withdrawn NCT02636803 Phase 2 oxfendazole;albendazole
34 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
35 The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren Completed NCT01640626 Phase 1
36 Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers. Completed NCT03192449 Phase 1 Albendazole.
37 A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males Completed NCT01755637 Phase 1 Albendazole
38 Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults Completed NCT02126462 Phase 1
39 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
40 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
41 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
42 Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® in Healthy Adults Completed NCT01717950 Phase 1
43 Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel, With or Without a CpG ODN Adjuvant, in Healthy Adults Completed NCT02143518 Phase 1
44 Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Na-GST-1/Alhydrogel®, With or Without a CPG ODN Adjuvant, in Gabonese Adults Completed NCT03373214 Phase 1
45 Phase I Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With Different Doses of the Novel Immunostimulant GLA-AF in Healthy Adults Completed NCT01385189 Phase 1
46 Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil) Completed NCT03173742 Phase 1 T1, T2, T3;T1,T3,T2;T2,T1,T3;T2,T3,T1;T3,T1,T2;T3,T2,T1
47 Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With or Without GLA-AF in Brazilian Adults Completed NCT01261130 Phase 1
48 A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers Completed NCT03035760 Phase 1 Oxfendazole
49 Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants Unknown status NCT02714348
50 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole

Search NIH Clinical Center for Parasitic Helminthiasis Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Antihelminthic [EPC]

Cochrane evidence based reviews: helminthiasis

Genetic Tests for Parasitic Helminthiasis Infectious Disease

Anatomical Context for Parasitic Helminthiasis Infectious Disease

MalaCards organs/tissues related to Parasitic Helminthiasis Infectious Disease:

Testes, Liver, Skin, Colon, Breast, Bone, Whole Blood

Publications for Parasitic Helminthiasis Infectious Disease

Articles related to Parasitic Helminthiasis Infectious Disease:

(show top 50) (show all 1557)
# Title Authors PMID Year
Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. 61 54
19471606 2008
[Toxocariasis in children--difficult clinical problem]. 54 61
18807488 2008
Eosinophil cationic protein as a possible marker of active human Toxocara infection. 61 54
11703226 2001
Hyperimmunoglobulinemia E in the absence of atopy and filarial infection: the Huaorani of Ecuador. 61 54
11191097 2000
Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. 54 61
11060486 2000
Possible relationship between allergic disease and infection by Giardia lamblia. 61 54
8452315 1993
Chemical composition and broad-spectrum anthelmintic activity of a cultivar of toothache plant, Acmella oleracea, from Mizoram, India. 61
32401104 2020
FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis? 61
32387059 2020
Impact of Different Sampling Schemes for Decision Making in Soil-Transmitted Helminthiasis Control Programs. 61
31829425 2020
Community-based door to door census of suspected people living with epilepsy: empowering community drug distributors to improve the provision of care to rural communities in Cameroon. 61
32503495 2020
The risk of nutrient intake and helminthiasis to experience underweighted among elementary school students. 61
32545048 2020
Ricobendazole nanocrystals obtained by media milling and spray drying: Pharmacokinetic comparison with the micronized form of the drug. 61
32512225 2020
A Case-Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis. 61
32494582 2020
Contrasting serum biomarker profiles in two Colombian populations with different risks for progression of premalignant gastric lesions during chronic Helicobacter pylori infection. 61
32447242 2020
Missed opportunity of deworming a Maasai boy from nomadic family leading to life threatening intestinal obstruction. 61
32494353 2020
A Cross-Sectional Study of Seroprevalence of Strongyloidiasis in Pregnant Women (Peruvian Amazon Basin). 61
32375325 2020
Genomic studies on Strongyloides stercoralis in northern and western Thailand. 61
32404172 2020
Soil-transmitted helminthiasis in four districts in Bangladesh: household cluster surveys of prevalence and intervention status. 61
32397986 2020
National surveillance on soil-transmitted helminthiasis in the People's Republic of China. 61
31958411 2020
Nanotechnological improvement of veterinary anthelmintics. 61
32448112 2020
Helminth infections and immunosenescence: The friend of my enemy. 61
32007545 2020
Praziquantel and risk of visual disorders: Case series assessment. 61
32294081 2020
Assessing expanded community wide treatment for schistosomiasis: Baseline infection status and self-reported risk factors in three communities from the Greater Accra region, Ghana. 61
32339185 2020
Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics. 61
32166776 2020
The Elimination of Neglected Tropical Diseases: A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 61
31402376 2020
Integrated community-based intervention for urinary schistosomiasis and soil-transmitted helminthiasis in children from Caxito, Angola. 61
31290969 2020
Haemoparasitic Infections in Cattle from a Trypanosoma brucei Rhodesiense Sleeping Sickness Endemic District of Eastern Uganda. 61
32046044 2020
Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: Adverse events in children from 2 to 15 years in Bengo province, Angola. 61
32160223 2020
Engagement of the National Institute of Parasitic Diseases in control of soil-transmitted helminthiasis in China. 61
32563326 2020
Influence of malaria, soil-transmitted helminths and malnutrition on haemoglobin level among school-aged children in Muyuka, Southwest Cameroon: A cross-sectional study on outcomes. 61
32226023 2020
Malaria Parasitemia in Febrile Patients Mono- and Coinfected with Soil-Transmitted Helminthiasis Attending Sanja Hospital, Northwest Ethiopia. 61
32089868 2020
On the Work of Alexander of Tralles. 61
32390447 2019
Gaps and barriers in interventions for the control of soil-transmitted helminthiasis among school-age children in an endemic area of the Philippines: a school-based point-of-view. 61
31391522 2019
Challenges in the control of soil-transmitted helminthiasis in Sichuan, Western China. 61
31404523 2019
Prevalence and risk factors of intestinal parasitic infestations among preschool children in Sekota town, Waghimra zone, Ethiopia. 61
31722686 2019
State of deworming coverage and equity in low-income and middle-income countries using household health surveys: a spatiotemporal cross-sectional study. 61
31558383 2019
Community perceptions of mass drug administration for soil-transmitted helminthiasis and schistosomiasis in selected schools in the Philippines. 61
31590687 2019
Assessing competence for helminthiases: A lesson learnt from national contest of parasitic diseases in China in 2012-2016. 61
31299284 2019
From the feces to the genome: a guideline for the isolation and preservation of Strongyloides stercoralis in the field for genetic and genomic analysis of individual worms. 61
31640777 2019
Efficacy of Ozoroa pulcherrima Schweinf methanolic extract against Schistosoma mansoni-induced liver injury in mice. 61
31453126 2019
Prevalence and associated factors of soil transmitted helminthes among pregnant women attending antenatal care in Maytsebri primary hospital, North Ethiopia. 61
31585533 2019
The Relationship of Gender, School Sanitation and Personal Hygiene with Helminthiasis at Juhar Karo Regency in North Sumatera Province, Indonesia. 61
32002082 2019
Epidemiological findings and policy implications from the nationwide schistosomiasis and intestinal helminthiasis survey in Sudan. 61
31488219 2019
Risk of Soil-Transmitted Helminthiasis among Agrarian Communities of Kogi State, Nigeria. 61
31517465 2019
Helminthiasis among North Koreans: a chronic public health challenge. 61
31818237 2019
Soil-Transmitted Helminthiasis in Children from a Rural Community Taking Part in a Periodic Deworming Program in the Peruvian Amazon. 61
31309921 2019
Helminthiases in North Korea: a neglected public health challenge. 61
31658422 2019
Therapeutic efficacy of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic methods. 61
31369562 2019
Anti-Ascaris suum immunoglobulin Y as a novel biotechnological tool for the diagnosis of human ascariasis. 61
31409433 2019
Efficacy and Safety of Ascending Dosages of Tribendimidine Against Hookworm Infections in Children: A Randomized Controlled Trial. 61
30496350 2019

Variations for Parasitic Helminthiasis Infectious Disease

Expression for Parasitic Helminthiasis Infectious Disease

Search GEO for disease gene expression data for Parasitic Helminthiasis Infectious Disease.

Pathways for Parasitic Helminthiasis Infectious Disease

Pathways related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.58 TSLP IL9 IL5 IL4 IL33 IL13
Show member pathways
13.3 STAT6 IL9 IL5 IL4 IL13 IL10
Show member pathways
13.25 STAT6 IL9 IL5 IL4 IL33 IL13
Show member pathways
13.21 IL9 IL5 IL4 IL13 IL10 CD4
Show member pathways
12.75 RNASE3 IL9 IL5 IL4 IL13 IL10
Show member pathways
12.51 IL9 IL5 IL4 IL10 CD4
Show member pathways
12.49 STAT6 IL5 IL4 IL13 IL10 CD4
Show member pathways
12.37 TSLP STAT6 IL9 IL5 IL4 IL13
Show member pathways
12.17 IL9 IL5 IL4 IL13 IL10
Show member pathways
12.01 STAT6 IL9 IL4
12 11.89 IL5 IL4 IL10 CD4
13 11.87 STAT6 IL4 IL13 IL10
14 11.7 IL5 IL4 IL13
15 11.57 IL5 IL4 IL13
16 11.56 STAT6 IL5 IL4 IL10
17 11.44 IL4 IL13 IL10
18 11.22 STAT6 IL9 IL5 IL4 IL33 IL13
19 11.18 IL5 IL4 IL13 IL10 CD4
20 11.18 TSLP IL9 IL5 IL4 IL33 IL13
21 11.14 TSLP IL9 IL5 IL4 IL33 IL13
22 11.07 IL9 IL5 IL4 IL13 IL10
23 10.92 IL9 IL5 IL4 IL13 IL10
24 10.75 IL9 IL5 IL4 IL13

GO Terms for Parasitic Helminthiasis Infectious Disease

Cellular components related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TSLP SERPINA3 RNASE3 IL9 IL5 IL4
2 extracellular space GO:0005615 9.36 TSLP SERPINA3 RNASE3 MIR21 IL9 IL5
3 clathrin-coated vesicle membrane GO:0030665 9.33 EPGN CHRM2 CD4

Biological processes related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 TSLP STAT6 IL5 IL4 IL10 ICOSLG
2 positive regulation of cell proliferation GO:0008284 9.91 TSLP MIR21 IL9 IL5 IL4 EPGN
3 positive regulation of cold-induced thermogenesis GO:0120162 9.79 STAT6 IL4 IL13
4 positive regulation of inflammatory response GO:0050729 9.78 TSLP MIR21 IL33
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 TSLP IL4 IL13
6 T cell activation GO:0042110 9.69 IL4 ICOSLG CD4
7 positive regulation of B cell proliferation GO:0030890 9.65 IL5 IL4 IL13
8 negative regulation of endothelial cell apoptotic process GO:2000352 9.63 IL4 IL13 IL10
9 cytokine-mediated signaling pathway GO:0019221 9.63 STAT6 IL5 IL4 IL13 IL10 CD4
10 macrophage activation GO:0042116 9.6 IL4 IL13
11 positive regulation of immunoglobulin secretion GO:0051024 9.59 IL5 IL33
12 positive regulation of interleukin-10 secretion GO:2001181 9.58 IL4 IL13
13 positive regulation of mast cell degranulation GO:0043306 9.58 IL4 IL13
14 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.57 IL4 IL10
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL4 IL10
16 positive regulation of interleukin-5 production GO:0032754 9.54 TSLP IL33
17 type 2 immune response GO:0042092 9.52 IL4 IL10
18 immune response GO:0006955 9.5 IL9 IL5 IL4 IL13 IL10 CD4
19 regulation of isotype switching GO:0045191 9.49 IL4 IL10
20 positive regulation of macrophage activation GO:0043032 9.43 IL33 IL13 IL10
21 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL4 IL13
22 positive regulation of isotype switching to IgE isotypes GO:0048295 9.37 STAT6 IL4
23 positive regulation of interleukin-13 production GO:0032736 8.8 TSLP IL4 IL33

Molecular functions related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IL9 IL5 IL4 IL10 EPGN
2 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
3 cytokine activity GO:0005125 9.17 TSLP IL9 IL5 IL4 IL33 IL13

Sources for Parasitic Helminthiasis Infectious Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....